Why DexCom's Bold Turn Represents an Opportunity

Sometimes, the best way to fix a mistake is to double down on it. That’s exactly what DexCom, the manufacturer of continuous glucose monitors (CGMs), is doing. Although the company suffered a significant setback last year, now is the time to take a closer look at the stock. The "mistake” of shifting strategy to the larger type 2 diabetes market was not a poor decision, but rather poorly executed. The stock crashed, but this correction presents an opportunity. With 38.4 million diabetics in the U.S. and less than 10% being type 1, the type 2...